GRCL - סך החוב של החברה Gracell Biotechnologies Inc.

Gracell Biotechnologies (GRCL) innovative CAR-T therapy methods are protected by global patents, ensuring sustainable demand and high profitability. This chart illustrates that the asset's market value is 0.02. Production relies on automated sterile laboratories with excellent equipment durability. Furthermore, the business's success is based on scientific achievements and alliances with pharmaceutical leaders, remaining independent of general economic cycles and GDP dynamics.

The market assesses Gracell Biotechnologies (GRCL) as a high-risk asset, where the total liabilities of 0.02 reflect the overall credit load and the company's ability to service its debt capital. By analyzing the volume of borrowed funds, an investor can see the biotech startup's dependence on external financing, which is critically necessary to cover costly developments in the field of onco-immunology until the drugs reach commercialization.